Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
193 participants
INTERVENTIONAL
2016-06-30
2018-07-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The secondary objectives of the study are to evaluate the effects of BNC210 on anxiety, depression, global functioning and patient reported outcomes in patients with PTSD. Safety and tolerability of BNC210 will also be assessed. Study participants will receive 12 weeks of blinded treatment followed by a 3 week follow-up period.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)
NCT04951076
Xenon Inhalation for Treatment of Posttraumatic Stress Disorder
NCT03635827
A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
NCT05193409
A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder
NCT05103657
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
NCT06510504
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BNC210 600 mg b.i.d.
Suspension administered orally for 12 weeks.
BNC210
BNC210 300 mg b.i.d.
Suspension administered orally for 12 weeks.
BNC210
BNC210 150 mg b.i.d.
Suspension administered orally for 12 weeks.
BNC210
Placebo b.i.d.
Suspension administered orally for 12 weeks.
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BNC210
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female between 18 and 70 years of age, inclusive.
* Diagnosed with current PTSD as defined by the CAPS-5 for DSM-5.
* Currently not using any psychiatric medications except for:
* No more than one selective serotonin reuptake inhibitor (SSRI) (fluvoxamine is excluded) or serotonin noradrenaline reuptake inhibitor (SNRI) within the licensed prescribing dose range. Subjects must have been on a stable dose for at least 3 months prior and through Screening, with the intent to remain on the same dose through to Week 16.
* As needed (PRN) use of benzodiazepines (BZD) at a frequency not exceeding 2 days per week in the 3 months prior to Screening. The total dose must not exceed 30 mg/day in diazepam equivalents.
* Subjects not currently receiving psychotherapy except long term supportive counseling or subjects that have received intensive regular psychotherapy for a minimum of three months prior to Screening.
* Females of childbearing potential must have a negative serum pregnancy. Females not of childbearing potential must be postmenopausal. Sterilized male patients must be at least 1 year post-vasectomy to be considered of non-child bearing potential. Females and males of childbearing potential must agree to use two effective methods of contraception.
Exclusion Criteria
* Failed more than three trials of antidepressant medication(s) prescribed for the treatment of PTSD. Each trial must have lasted at least 6 weeks to be considered a failed attempt. A trial that was terminated due to intolerability or side effects does not constitute a failed attempt.
* The use of psychiatric medications within 2 weeks of Screening except for SSRIs, SNRIs or limited PRN BZD use as per inclusion criterion 4. Restricted psychiatric medications include (but are not limited to) antidepressants not allowed by inclusion criterion 4, antianxiety drugs (except limited BZD use per inclusion criterion 4), mood stabilizers, stimulants, antipsychotics, hypnotics and acetylcholinesterase inhibitors.
* History of significant traumatic brain injury.
* Depression as measured by Montgomery-Äsberg depression scale (MADRS) rating \> 23.
* Bipolar and psychotic disorders as identified at Screening using the MINI International Neuropsychiatry Interview (V7.0) (M.I.N.I).
* A score ≥ 7 on the McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD) at Screening.
* History of seizure disorders, uncontrolled sleep apnoea or severe neurologic disease.
* Increased risk of suicide, defined as:
* Any previous suicide attempt disclosed by the participant at Screening using the Columbia Suicide Severity Rating Scale (C-SSRS).
* Any suicidal ideation with intent (yes to item 4 and / or 5) or suicidal behavior in the past year, as captured at Screening using the C-SSRS.
* A score \> 4 on item 10 of the MADRS at Screening.
* The use of alprazolam or flunitrazepam within 3 months of Screening.
* Any clinically significant abnormalities in laboratory test results, vitals signs, or ECG at Screening.
* Positive result for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C (HCV) at Screening.
* Any moderate to severe substance use disorder (any type) in the 12 months prior to Screening as identified by the DSM-5 using the M.I.N.I (V7.0).
* Current Australian serving Defense personnel or any member of the US military currently serving on active duty.
* Participants involved with ongoing insurance or workplace claims that in the opinion of the Investigator are likely to have an impact on the mental health, presentation or capacity of the patient to engage in the study.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bionomics Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oceanside, California, United States
Rancho Mirage, California, United States
Redlands, California, United States
Riverside, California, United States
Gainesville, Florida, United States
Jacksonville, Florida, United States
Lauderhill, Florida, United States
North Miami, Florida, United States
Oakland Park, Florida, United States
Orlando, Florida, United States
Hoffman Estates, Illinois, United States
Overland Park, Kansas, United States
New Bedford, Massachusetts, United States
Lincoln, Nebraska, United States
Las Vegas, Nevada, United States
Berlin, New Jersey, United States
Canton, Ohio, United States
Memphis, Tennessee, United States
Dallas, Texas, United States
San Antonio, Texas, United States
Penrith, New South Wales, Australia
Auchenflower, Queensland, Australia
Toowong, Queensland, Australia
Elizabeth Vale, South Australia, Australia
St Kilda, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BNC210.007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.